Friday, 17 Jan 2020

You are here

EULAR 2019 Report – Day 2

Editor's note: July 1 - 5, RheumNow is running the best of the EULAR 2019 meeting. It was a full and lively second day in Madrid with sessions dedicated to Lupus, RA, Sjogren’s, imaging, rare diseases, psoriatic arthritis and spondyloarthritis. Here are a few of the highlights from day 2 EULAR in Madrid. 

  • Riociquat in SSc-ILD: riociquat is approved in the US for pulmonary arterial hypertension and chronic thromboembolic pulmonary HTN and is now applied to 121 patients with early SSc (<18 mos. Symptoms) and limited scleroderma (mRSS 12-20).  This 52 week ended with a downward trend in skin thickness but did not achieve its primary endpoint (p=0.08).  However when they looked at the 20% of patients who had interstitial lung disease, they found significant reductions in FVC. This was encouraging as the drug was well tolerated.  OP0183
  • The Earlier the Better.  A longitudinal study from a Swedish RA registry examine 6559 RA patients enrolled since 1991 and shown that new, DMARD naïve RA patients, have overtime, demonstrated decreasing levels of joint activity (initial SJC, TJC), CRP, ESR, and increasing patient and evaluator global assessments.  Also decreasing was the time from symptom onset to diagnosis of RA.  So if RA is getting milder, it may well be that we are seeing them sooner, with more expedited diagnoses and hopefully earlier DMARD initiation.  THU0073
  • Machine Learning with Psoriatic Arthritis.  Dr. Ian McInnes presented a novel and futuristic analysis of PsA patients by applying “machine learning” to the secukinumab PsA trials that included >2,700 patients to identify clusters that may lead to more personalized treatment.  Overall they defined 13 clusters of PsA based on patterns of tender joint (TJ) and swollen joint (SJ) involvement. They plan on doing further study of other psoriatic manifestations such as skin and nail involvement to describe a range of phenotypes that explains PsA variability.  OP0114

 

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

CDC: 15% of US Adults are Physically Inactivie

All states and territories had more than 15% of adults who were physically inactive and this estimate ranged from 17.3 to 47.7%,  according to new state maps of adult physical inactivity prevalence released today by the Centers for Disease Control and Prevention (CDC).

RheumNow Podcast- The Down Side of Steroids (1.17.20)

Dr. Jack Cush reviews the journal reports and news from RheumNow.com. Be sure to register for RheumNow Live 3/13/2020 in Fort Worth Rheumnow.live.

RheumNow Podcast- Knee Pain Knockout (1.10.20)

Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com. The podcast covers: best therapies for dactylitis and enthesitis; we have a new knockout for knee pain in OA; and are you on the naughty or nice list when it comes to the new ACR-AF guidelines for arthritis? This and more. Tune in.

2019 Rheumatology Year in Review

2019 was a year marked by major advances, hallmark research, and big news items affecting rheumatology.   Herein you will find our top 10 list, formulated by what I think rheumatologists should know and what will likely change their standards and practice in 2020 and beyond. 

RheumNow Podcast - 2019 Rheumatology Year in Review

Dr. Jack Cush reviews highlights from 2019 on RheumNow.com. Topics covered in this annual review include: superheroes lost; venous thromboembolic events and JAKs; free medical tuition; women in rheumatology; 52 new drug approvals in 2019 and 330 drugs with a 2020 price hike; scleroderma disappointments; novel new treatments and newer tests; the boom of Shingrix; RheumNow.Live - and more.